0 results for 'health benefits'
Global AI Regulation: Southeast Asia Takes a 'Light Touch,' as China and the EU Play a Heavier Hand
Southeast Asia, and particularly Singapore, has taken a "light touch" in the regulation of AI. But the approach is not the same everywhere in Asia.The Challenge of AI Governance: The Blessing and the Curse of Safeguarding Personal Data
"Organizations must strike a balance by harnessing the benefits of AI while remaining vigilant against employee complacency and the exploitation of automated systems," write Frances M. Green and Karen Mandelbaum.Jury Awards Horizon $2.4 Million for Fraudulent Billing Against 3 NJ Health Care Providers
Horizon's complaint alleged it paid more than $2.6 million in claims that were fraudulently submitted by the defendants for medical services that were either not performed, not medically necessary, or not ordered by a licensed medical professional.Politician Trading: If You Can't Stop Them, Join Them
One company, Autopilot, is taking advantage of Congress members' advantage with a method for Joe Q. Public to trade like a politician.View more book results for the query "health benefits"
OIG Issues Unfavorable Opinion for Proposal to Share a Percentage of Savings
The requestor inquired as to whether the "proposed arrangement," as discussed below, would warrant sanctions under Sections 1128(b)(7) or 1128A(a)(7) of the Social Security Act (SSA) as they relate to the federal Anti-Kickback Statute (AKS). The opinion concludes that, if undertaken, the proposed arrangement would generate prohibited remuneration under the AKS.Delray Beach Financial Adviser Indicted in Alleged Illegal Tax Shelter Scheme
Stephen T. Mellinger III was indicted on charges of defrauding the IRS in 2013 by promoting an illegal tax shelter.People in the News—Sept. 30, 2024—Panitch Schwarze, Fox Rothschild
Intellectual property law firm Panitch Schwarze Belisario & Nadel announced that Julianna L. Hunt has joined the firm as an associate.'Unfair Business Practices'?: Lawsuits Allege Big Pharma Multiple Sclerosis Drug Monopoly
"Biogen's anticompetitive conduct, and the PBMs' participation in it, delayed and substantially diminished the sale of generic Tecfidera in the United States, and unlawfully enabled Biogen to sell Tecfidera and Vumerity at artificially inflated units and prices," according to the allegations in three complaints accusing Biogen of monopolizing the multiple sclerosis drug market.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
Criminal Division's Evaluation of Corporate Compliance Programs: September 2024 Updates Review
Brought to you by NAVEX Global
Download Now
Data Management and Analytics: The Key to Success for Legal Operations
Brought to you by DiliTrust
Download Now
Small Law Firm Playbook: The Expert's Guide to Getting the Most Out of Legal Software
Brought to you by PracticePanther
Download Now
Strong & Hanni Solves Storage Woes--Learn How You Can, Too
Brought to you by Filevine
Download Now